Madrigal Pharmaceuticals Inc

NASDAQ: MDGL

MDGL Chart and Intraday Price

MDGL Company Data

Asset Type Stock
Exchange NASDAQ
Currency USD
Country USA
Sector LIFE SCIENCES
Industry PHARMACEUTICAL PREPARATIONS
Address 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA, US
Fiscal Year End December
Latest Quarter 12/31/2023
Market Cap 5,006.78M USD
Shares Outstanding 19,897,400
Madrigal Pharmaceuticals Inc is a biopharmaceutical company in the clinical stage, primarily focused on creating treatments for non-alcoholic steatohepatitis (NASH), a liver disease. Their main product in development is resmetirom, aimed at treating NASH through a novel approach as a liver-directed thyroid hormone receptor beta agonist. Currently, resmetirom is undergoing Phase 3 clinical trials. The company operates out of West Conshohocken, Pennsylvania.

MDGL Articles

Huge Warren Buffett Purchase Highlights Hot Insider Buying
Warren Buffett's Berkshire Hathaway has bolstered its stake in Occidental Petroleum with a huge purchase of shares. Insider buying is heating up in general.
Trey Thoelcke
Published:

See Which Inside Buyers Are Scooping Up More Shares Now
Some of the biggest insider buying since the Thanksgiving holiday has come from repeat buyers, including Bill Ackman, who continues to build his stake in a real estate firm.
Trey Thoelcke
Published:

Insiders Are Loading Up on These Biotech and Energy Stocks
Notable insider buying in the past week included biotech and energy companies, including some that have just gone public. Also, renowned hedge fund manager Bill Ackman continues building a stake in a...
Trey Thoelcke
Published: